H. Anne Pereira, Ph.D.

---

Summary

My laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.

---

Research

This laboratory investigates the role of a novel inflammatory mediator known as CAP37. We focus on the significance of this protein in host defense against severe infections including infections of the eye and in various inflammatory mediated diseases such as atherosclerosis and Alzheimer's disease. We currently employ a combination of cellular, immunological, biochemical and molecular approaches at the in vitro and in vivo level to solve these questions. Our long-term goals are to design new and effective antibiotics and anti-inflammatory therapeutics.

Patents

---

Publications & Presentations

26. Ruan X, Chodosh J, Callegan M C, Booth M C, Lee T D, Kumar P, Gilmore M S, Pereira H A. Corneal expression of the inflammatory mediator CAP37. Investigative ophthalmology & visual science. 2002; 43 : 1414-21

27. Lee T D, Gonzalez M L, Kumar P, Chary-Reddy S, Grammas P, Pereira H A. CAP37, a novel inflammatory mediator: its expression in endothelial cells and localization to atherosclerotic lesions. The American journal of pathology. 2002; 160 : 841-8

28. Pereira H A. Cationic antimicrobial protein of Mr 37 kDa: a multifunctional inflammatory protein. Chinese medical journal. 2001; 114 : 9-13

29. Polikandritou Lambros M, Sheu E, Lin J S, Pereira H A. Interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes. Biochimica et biophysica acta. 1997; 1329 : 285-90

30. Brackett D J, Lerner M R, Lacquement M A, He R, Pereira H A. A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats. Infection and immunity. 1997; 65 : 2803-11

Grants

1. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2023. End Date: 2028.

2. Vision Science Training Program. NIH. Start Date: 2021. End Date: 2026.

3. STTR Phase 1: Multi-target Peptide Drug for Alzheimer's Disease. NIA. Start Date: 2024. End Date: 2025.

4. STTR Phase 1: Novel Ophthalmic Product for Corneal Infections and Injuries. NIH. Start Date: 2021. End Date: 2023.

5. Oklahoma Shared Clinical and Translational Resources. NIH. Start Date: 2018. End Date: 2023.

Awards and Honors

6. American Association for the Advancement of Sciences (AAAS)Fellow. Date: 2014.


7. American Association of Colleges of Pharmacy (AACP)Fellow, Academic Research Fellows Program. Date: 2013.


8. OCNS. Oklahoma Center for Neuroscience - Special Recognition Award. Date: 2011.


9. OUHSC. Henry Zarrow Presidential Professorship. Date: 2008.


10. Grace & Franklin Bernsen Foundation. Finalist, Grace & Franklin Bernsen Foundation Most Promising New Business Award. Date: 2007.

Education

1. Degree: Ph D. University of Melbourne. Date: 1982.


2. Degree: BSc (Honours) First class honours & First Place. University of Melbourne. Date: 1976.


3. Degree: BS. University of Melbourne. Date: 1975.

Administrative Assignments

1. Role: Dean. Scope: University. Description: Dean of the Graduate College. Responsible for Graduate Programs on the Health Sciences Campus and the Postdoctoral Office. Date: 2014.
Read More
2. Role: Associate Dean. Scope: College. Description: Responsible for Oversight of research activities in the College of Pharmacy, mentoring junior faculty and trainees. Date: 2009.
Read More